ST-segment elevation myocardial infarction (STEMI)

At TCT Connect 2020, Byeong-Keuk Kim presented the results of the TICO-STEMI, from the randomized TICO trial of ticagrelor monotherapy vs ticagrelor with aspirin in ACS. Dejan Milasinovic provides a summary of the key messages.

Luis Ortega-Paz provides a summary of the key messages from the COMPARE CRUSH trial. He also discusses the main findings and recommendations in clinical practice with Georgios Vlachojannis who presented the results during TCT Connect 2020. 

Vijay Kunadian provides a summary of the coronary & structural late-breaking studies presented during TCT Connect 2020 and shares some take-home messages. See how these studies might influence your daily practice!

View reviews and take-home messages from a selection of major Late-breaking Clinical Trials in Interventional Cardiology released at the 2020 online edition of TCT Connect. Check out the list here!

Consult this case of a 38-year-old male who presented in the ER with acute chest pain after he had received first cycle of chemotherapy with cisplatin, bleomycin and etoposide for gestational cell tumour with mesenteric mass. The angiogram showed grade IV thrombus in proximal LAD...

The goal of the present post hoc analysis of the CLIMA registry was to establish the relationship between calcified nodules (CNs) with (CND) or without (CNWD) disruption of the superficial intimal fibrous layer and one-year occurrence of target lesion myocardial infarction (MI) and/or cardiac death.

ESC Congress 2020: Tabassome Simon (Paris, France) discusses with Francesco Costa the results of REALITY trial which supports the use of a restrictive strategy for blood transfusion in MI patients with anemia.

In this unusual STEMI case of a 75 year old hypertensive woman, find out how medical history can guide the therapeutic choices and how the interventional cardiologist can resist stent implantation...

The MIRTOS trial, which included STEMI patients receiving DAPT and thrombolysis ‘together’, aimed to evaluate whether ticagrelor could improve microvascular perfusion and reduce MACE compared to clopidogrel

The results of the FABOLUS FASTER trial clearly highlight that a high residual platelet reactivity persists when targeting platelet activation by inhibition of the P2Y12 receptor either with Prasugrel or Cangrelor, while tackling the mechanism of platelet adhesion thought the inhibition of GPIIB/IIIA might almost completely...